NeuroMab™ Anti-EGFR BBB Shuttle Antibody,Clone NR3057P

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Mouse

Clone Number

NR3057P

Applications

FC; In Vitro; Inhib

Relevant Diseases

Alzheimer's Disease; Pain; Multiple Sclerosis

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

EGFR

Official Name

EGFR

Full Name

Epidermal Growth Factor Receptor

Alternative Names

Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Product Pictures

FCM

Figure 1 shows flow cytometry of DNA in nuclei obtained from HN5 cells after four days of in vitro incubation in DMEM-2%FCS alone or in DMEM-2%Fr containing anti-EGFR mAb (156nM) or EGF (10nM) analyze.

Figure 1 shows the DNA histogram

FCM

Figure 2 shows flow cytometry of DNA in nuclei obtained from HN5 cells after four days of in vitro incubation in DMEM-2%FCS alone or in DMEM-2%Fr containing anti-EGFR mAb (156nM) or EGF (10nM) analyze.

Figure 2 shows the percentage of cells at each stage.

FuncS

Figure 3 shows the effect of antibodies directed against EGFR or its Fab fragments on the binding of I 25 -EGF to human bladder cancer cell line EJ.

FuncS

Figure 4 shows the effect of antibodies directed against EGFR or its Fab fragments on the binding of 25 I-TGFo to human bladder cancer cell line EJ.

FuncS

Figure 5 shows Scatchard plots of I-EGF binding to EJ cells in the absence or presence of monovalent and bivalent mAb ICR9.

FuncS

Figure 6 shows Scatchard plots of I-EGF binding to EJ cells in the absence or presence of monovalent and bivalent mAb ICR62.

FuncS

Figure 7 shows the effect of treatment with antibodies against EGFR or its Fab fragments on the growth of HN6 cells in vitro (the picture shows other head and neck cancer cell lines overexpressing the EGF receptor.

FuncS

Figure 8 shows the effect of treatment with antibodies against EGFR or its Fab fragments on the growth of HN6 cells in vitro (Figure 8 Other head and neck cancer cell lines overexpressing EGF receptors (Figure and TGFa-induced proliferation of quiescent human foreskin fibroblasts) 9).

FuncS

Figure 9 shows the effect of treatment with antibodies against EGFR or its Fab fragments on the growth of HN6 cells in vitro (Figure 9).

FuncS

Figure 10 shows titration curves showing inhibition of 125I-EGF binding to EJ cells by sera taken at the indicated times. A, patient 8 (20 mg); B, patient 10 (40 mg); or C, patient 13 (100 mg).

FuncS

Figure 11 shows the development of human anti-rat antibodies in serum of patient No. 9 after injection of 20 mg ICR62, as shown by binding of intact ICR62 Fab ICR62 and scFv ICR62.

FuncS

Figure 12. Development of human anti-rat antibodies in serum of patient No. 11 following injection of ICR62 shown to bind intact ICR62 Fab ICR62 but not scFv ICR62 Sequence listing shows DNA and deduced amino acid sequence of ICR62 variable region Replication of ICR62 and ICR64 Chain and light chain, CDRs are shown in square brackets.

Publications